Two Onc Docs Soft Tissue Sarcomas 2025 UPDATE
28 snips
Sep 9, 2025 Delve into the latest insights on soft tissue sarcomas, featuring new FDA approvals and evolving diagnostic challenges. Discover the complexities of this rare category of tumors, which represent just 1% of adult cancers and include both noncancerous and aggressive forms. Learn about treatment strategies for various subtypes, including desmoid tumors and Kaposi's sarcoma, highlighting innovative surgical and chemotherapy advancements. The emphasis is on a multidisciplinary approach to enhance patient outcomes.
AI Snips
Chapters
Transcript
Episode notes
Prioritize Surgery And Thoughtful Radiation
- Treat localized soft tissue sarcoma primarily with surgery aiming for limb-sparing approaches when possible.
- Use pre- or postoperative radiation selectively, weighing smaller volumes and wound-healing risk versus larger fields and doses.
Immunotherapy Added To Radiation Shows Promise
- Adding pembrolizumab to radiation improved 2-year disease-free survival in stage 3 high-grade extremity sarcomas in SARC0032.
- Overall survival data remain pending and toxicity was modestly increased.
Doxorubicin Is First-Line Systemic Therapy
- Use doxorubicin as first-line systemic therapy for metastatic soft tissue sarcoma, with ifosfamide added selectively.
- Reserve combination regimens for subtype-specific sensitivity and to balance response versus toxicity.